An app that gives people with ALS their voice back sounds like an unqualified win. The real story is who gets it, who pays, and how far the gap remains between a headline and actual access inside the healthcare system.
Breakthrough apps exist, but access and integration are where the cost shows up
KSL.com reported in March 2026 on a man who developed an app that gives people with ALS their voice back: David Betts, a Pittsburgh-area consultant with no coding background, built “Talk to Me, Goose!” in 80 days after his wife was diagnosed with ALS at 57. The app uses voice cloning from as little as 45 seconds of audio and an AI assistant called Merlin to turn short phrases into full sentences, reducing the awkward pauses that plague traditional text-to-speech. It is free for ALS patients in the U.S. and Canada through a partnership with the nonprofit Live Like Lou and won the 2026 Zero Project Award for reducing barriers for people with disabilities. KSL.com has highlighted the human story and the technical achievement.
Behind that story, the cost of accessible technology for ALS is steep and uneven. According to Project Revoice and related sources, voice-banking options for patients range from about $99 per year to one-time fees of $999 or more; dedicated platforms like Acapela MyOwnVoice can run to $1,499. Advanced augmentative and alternative communication (AAC) devices with features such as eye-tracking often cost between $10,000 and $15,000, which the Observer reported has “left millions effectively voiceless” for decades. An ALS Association-led study released in 2025 found that first-year care costs for ALS patients exceed $47,000, with out-of-pocket costs around $6,802 compared to $2,050 for typical Medicare beneficiaries. Journal of Managed Care and Pharmacy research from 2024 shows costs rising by stage: early-stage ALS averages about $31,411 per year, mid-stage about $51,481, and late-stage about $121,903. So even when an app is free, the ecosystem of devices, connectivity, literacy, and care coordination creates a hidden cost that many families cannot meet.
Healthcare integration is where the divide sharpens. A German study of more than 11,000 assistive technology devices provided to 1,494 ALS patients found that only about 70% of requested devices were delivered. Failure rates were high for the tools that matter most: 52% for powered wheelchairs, 39% for communication devices, and 21% for orthoses. Insurance refusal, patient decisions, and delivery delays were the main obstacles. Research in the American Journal of Physical Medicine and Rehabilitation and elsewhere notes that assistive technology is central to ALS care because disease-modifying drugs have only modest effects on survival, yet most studies of these devices are small pilots and evidence across disease stages remains thin. So the gap is not only cost but also whether the system can reliably get the right technology to the right person in time.
Free apps do not fix the system
Initiatives like Talk to Me, Goose!, ElevenLabs’ free voice cloning for ALS patients, and Apple’s on-device Personal Voice (which needs only 15 minutes of audio) are aimed at closing the access gap. But they sit alongside a market where other options still charge hundreds or thousands of dollars and where many patients lack the literacy, internet access, or timing to use them. Project Revoice and similar resources advise patients not to wait: voice banking should happen while speech is still possible. For those who miss that window or cannot afford the hardware that runs the software, the “free” app is out of reach. A study of online ALS communities cited in Frontiers in Neurology reported barriers including inadequate device design, high cost, limited insurance coverage, and delays in getting equipment. The same research noted that communication technologies can empower patients to generate and self-report health data, improving disease management when they are actually in use. The disconnect is between what works in principle and what reaches the average patient. Medicare and insurance data add to the picture: only about 5% of Medicare beneficiaries with ALS received edaravone in their first year post-diagnosis, and about 31% received riluzole, below what guidelines would suggest. That underuse of proven drugs hints at the same access and coordination problems that affect assistive technology. So the hidden cost is not only the price tag of devices but the structural barriers that keep both drugs and technology from reaching patients in time.
What This Actually Means
Apps like “Talk to Me, Goose!” and initiatives from ElevenLabs, Apple Personal Voice, and others are genuine advances. The hidden cost is that they sit inside a system that still fails many patients: high device prices, uneven insurance coverage, and poor integration into routine care. KSL.com and CBS Pittsburgh have rightly celebrated the ingenuity of a husband building an app for his wife; the next step is to ask how many families can actually use it and how many are still left behind by device costs, insurance denials, and delays. Until accessibility is treated as part of healthcare delivery, not just innovation, the divide between breakthrough and benefit will remain. The headline is the app; the story is who still cannot reach it. Reducing that gap is the next challenge for developers, insurers, and policymakers alike.
What is ALS?
ALS (amyotrophic lateral sclerosis), also known as motor neuron disease or Lou Gehrig’s disease, is a rare, terminal neurodegenerative disease. It is defined by progressive loss of motor neurons that control voluntary movement. Symptoms typically include muscle stiffness, twitches, weakness, and wasting; over time, people lose the ability to eat, speak, move, and breathe without support. Up to 95% of people with ALS eventually lose natural speech, which is why voice cloning and AAC technology are so important. There is no cure; care focuses on symptom management, quality of life, and assistive technology to maintain communication and function as long as possible. First-year Medicare costs for ALS patients run to roughly $47,000, and out-of-pocket burdens are high, so the affordability of assistive technology is a central concern for families.
How does voice cloning help people with ALS?
Voice cloning uses a short sample of a person’s speech (from 45 seconds in some apps to 15 minutes in others) to build a synthetic voice that sounds like them. For someone with ALS who is losing the ability to speak, that means they can type or use other inputs and still “speak” in their own voice to family and caregivers. Apps like Talk to Me, Goose! add an AI assistant that expands short phrases into full sentences, cutting down the long pauses typical of letter-by-letter or word-by-word communication. The technology works best when people record their voice early, before speech is severely affected, which is why advocates urge patients not to wait. The hidden cost is that not everyone has the device, the broadband, or the support to do it in time. Free programmes and partnerships with groups like Live Like Lou help, but they do not replace the need for earlier diagnosis, better coverage of AAC devices, and faster delivery so that technology reaches patients while they can still use it.
Sources
KSL.com, CBS Pittsburgh, Project Revoice, PR Newswire, Observer, University of Luebeck